TRCT
CGTX icon

Tower Research Capital (TRC)’s Cognition Therapeutics CGTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.05K Buy
+5,339
New +$6.21K ﹤0.01% 4232
2025
Q4 		– Sell
-1,996
Closed -$2.69K – 5196
2025
Q3 		$2.69K Buy
+1,996
New +$2.72K ﹤0.01% 4597
2025
Q2 		– Sell
-2,444
Closed -$1.03K – 5285
2025
Q1 		$1.03K Sell
2,444
-18,526
-88% -$10.9K ﹤0.01% 4782
2024
Q4 		$14.7K Buy
20,970
+9,980
+91% +$4.93K ﹤0.01% 3450
2024
Q3 		$5.15K Buy
10,990
+359
+3% +$370 ﹤0.01% 4320
2024
Q2 		$17.6K Buy
10,631
+4,213
+66% +$8.4K ﹤0.01% 3827
2024
Q1 		$11.7K Buy
6,418
+1,551
+32% +$3.2K ﹤0.01% 3542
2023
Q4 		$9K Buy
4,867
+1,308
+37% +$1.73K ﹤0.01% 4448
2023
Q3 		$5.13K Sell
3,559
-703
-16% -$1.1K ﹤0.01% 4757
2023
Q2 		$7.8K Sell
4,262
-1,063
-20% -$2.25K ﹤0.01% 4524
2023
Q1 		$11K Buy
5,325
+1,131
+27% +$2.15K ﹤0.01% 4190
2022
Q4 		$9K Buy
4,194
+3,257
+348% +$6.58K ﹤0.01% 4171
2022
Q3 		$2K Sell
937
-970
-51% -$2.02K ﹤0.01% 5531
2022
Q2 		$4K Buy
+1,907
New +$4.93K ﹤0.01% 5178

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Tower Research Capital (TRC)'s CGTX Position: Q1 2026 in Review

Tower Research Capital (TRC) opened a new position in Cognition Therapeutics (CGTX) in Q1 2026: 5,339 shares worth $4.05K. The stake represents ﹤0.01% of the portfolio and ranks #4232 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in CGTX as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in CGTX in Q2 2022 and has held it in 14 quarters since. The position peaked at $17.6K in Q2 2024. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Tower Research Capital (TRC) held 5,339 shares of Cognition Therapeutics worth $4.05K as of Q1 2026.
  • Cognition Therapeutics was a new Tower Research Capital (TRC) position in Q1 2026.
  • Cognition Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4232 holding.
  • Tower Research Capital (TRC) first reported a position in Cognition Therapeutics in Q2 2022 and has held it in 14 quarters since.
  • Tower Research Capital (TRC)'s Cognition Therapeutics position peaked at $17.6K in Q2 2024.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.